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http://dx.doi.org/10.1016/j.ccr.2012.12.021SUMMARYWe report a paracrine effect whereby endothelial cells (ECs) promote the cancer stemcell (CSC) phenotype of
human colorectal cancer (CRC) cells. We showed that, without direct cell-cell contact, ECs secrete factors
that promoted the CSC phenotype in CRC cells via Notch activation. In human CRC specimens, CD133
and Notch intracellular domain-positive CRC cells colocalized in perivascular regions. An EC-derived,
soluble form of Jagged-1, via ADAM17 proteolytic activity, led to Notch activation in CRC cells in a paracrine
manner; these effects were blocked by immunodepletion of Jagged-1 in EC-conditioned medium or
blockade of ADAM17 activity. Collectively, ECs play an active role in promoting Notch signaling and the
CSC phenotype by secreting soluble Jagged-1.INTRODUCTION
Colorectal cancer (CRC) is the second-leading cause of cancer
death in the United States, with 50,000 patients dying each
year as a result of metastatic disease that is refractory to
systemic therapy (American Cancer Society, 2010; Davies and
Goldberg, 2008, 2011). Although there are now six Food and
Drug Administration approved drugs for the treatment of meta-
static CRC, median overall survival remains less than 2 years
(Davies and Goldberg, 2011). Targeted therapies, including anti-
angiogenic therapies, have not dramatically improved clinical
outcomes of patients with metastatic CRC (Saltz et al., 2008).
A better understanding of the biology of CRC is imperative for
the development of more effective therapeutic approaches that
can benefit patients with CRC.Significance
We found that endothelial cell (EC)-derived soluble factors enha
ance of colorectal cancer (CRC) cells. This suggests that ECs in
for blood flow—they also actively secrete factors that promote
ADAM17-cleaved formof Jagged-1 in EC-conditionedmedium
type in CRC cells. Identification of this mechanism, by which th
should provide the foundation for more refined targeted t
malignancies.
CThere is evidence for the existence of cancer stem cells (CSCs)
in CRC (Barker et al., 2009; Du et al., 2008; Huang et al., 2009;
O’Brien et al., 2007; Ricci-Vitiani et al., 2007). Because of the
intrinsic stem cell-like properties of CSCs, this subpopulation
of tumor cells is believed to not only initiate and sustain tumor
growth but also mediate chemoresistance (Al-Hajj, 2007; Wicha
et al., 2006). Notably, a number of studies suggest that CSCs
exist in a state of flux and the CSC phenotype can be enhanced
by microenvironmental influences (Butler et al., 2010a; Rosen
and Jordan, 2009). Therefore, the development of CSC- and/or
microenvironment-targeting strategies that could eliminate the
CSC population is critical for improving the clinical outcomes
of patients with CRC.
Several groups have reported that tumor progenitor cells
reside in perivascular niches in certain types of cancers (Butlernce the cancer stem cell (CSC) phenotype and chemoresist-
the tumor microenvironment are more than simply conduits
tumor cell survival and growth. We further defined a soluble,
that activates Notch signaling and promotes theCSCpheno-
e tumor microenvironment can promote the CSC phenotype,
herapies for the treatment of both early- and late-stage
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Figure 1. Endothelial Cells Promote the CSC Phenotype in CRC Cells In Vitro
(A) Freshly isolated xenografted human CRC (xhCRC) cells were cocultured with freshly isolated human liver parenchyma endothelial cells (LPECs), and the
Aldefluor-positive xhCRC cell population was determined.
(legend continued on next page)
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Whether perivascular niches of CSCs exist in other solid tumors,
including CRCs, is yet unclear. More importantly, how ECs
function to establish and maintain tumor-initiating-cell niches
remains to be further elucidated. Understanding the mecha-
nisms by which ECs promote the CSC phenotype will provide
the foundation for the development of novel and refined CSC-
targeting approaches. The purpose of this study was to under-
stand the role of ECs in mediating the CSC phenotype of CRC
cells and the mechanism by which this occurs.
RESULTS
Coculture with ECs Promotes the Cancer Stem Cell
Phenotype of CRC Cells
In order to understand tumor-EC cross-talk, and particularly
the potential role of ECs in promoting the CSC phenotype of
CRC cells, we first conducted a coculture experiment. We
used freshly isolated human CRC cells from surgical specimens
after establishing a first passage xenograft in mice (xhCRC) to
expand the number of cells. We also used freshly isolated liver
parenchyma ECs (LPECs) labeled with GFP-Luc or mCherry in
tissue culture. After coculture for three days, xhCRC cells were
isolated by fluorescence-activated cell sorting (FACS) and
were analyzed for potential enrichment of the population with
CSC characteristics. As shown in Figure 1A, coculture with
LPECs increased the fraction of xhCRC cells that were Aldefluor
positive, a population presumably enriched for CSCs (Huang
et al., 2009). Similarly, coculture of LPECs with CRC cells in-
creased the percentage of cells that were CD133 positive (Fig-
ure 1B). Coculture with LPECs also increased the percentage
of xhCRC cells with in vitro sphere-forming ability (4-fold; p <
0.05; Figure 1C). Collectively, these data suggest that ECs
could promote the CSC phenotype of cocultured CRC cells
ex vivo. Similar results were also obtained from in vitro experi-
ments with the established human CRC cell line HCT116 and
immortalized human umbilical vein endothelial cell line RF24
(Figures S1A and S1B available online).
Endothelial Cell-Conditioned Medium Promotes the
Cancer Stem Cell Phenotype of CRC Cells
To determine whether the effect observed above required direct
cell-cell contact or whether it is mediated by soluble factors
secreted by ECs, we cultured freshly isolated human CRC
(hCRC) cells in conditioned medium obtained from freshly iso-
lated LPECs, or control medium (MEM containing 1% FBS);(B) Freshly isolated xhCRC cells were cocultured with freshly isolated LPECs, an
(C) Freshly isolated xhCRC cells were cocultured with freshly isolated LPECs, an
(D) Freshly isolated human CRC (hCRC) cells were treated with LPEC-derived
determined.
(E) Freshly isolated humanCRC (hCRC) cells were treated with LPEC-derived cond






cultures of freshly isolated hCRC c
(G) xhCRC cells were FAC-sorted by the Aldefluor assay into high, middle, and
populations were treated with LPEC CM in parallel; the Aldefluor assay was then r
to determine which ALDH fraction could be enriched for CSCs by EC CM.
(H) xhCRC cells were FAC-sorted for high, middle, and lowCD133 expression (upp
CM in parallel; the flow cytometry analysis on CD133was then repeated (middle pa
CD133 fraction could be enriched for CSCs by EC CM.
*p < 0.05, mean ± SEM. See also Figure S1.
Cafter exposure to the CM, hCRC cells were analyzed for the
CSC phenotype. Compared to control medium, LPEC CM en-
riched the Aldefluor-positive hCRC cell population by 16-fold
(Figure 1D) and enriched the CD133-positive hCRC cell popula-
tion by 7-fold (Figure 1E), after 72 hr treatment. In addition,
LPEC CM treatment also increased sphere-forming capability
of hCRC cells by over 6-fold (Figure 1F). Upon serial passaging,
hCRC cells treated with LPEC CM demonstrated significantly
greater capability (10–15-fold increase) to form secondary and
tertiary tumor spheres (Figure 1F). We were able to obtain similar
results from established CRC cell lines (HCT116 and HT29)
treated with CM collected from established endothelial cell lines
(RF24 and HDMECs) or LPECs (Figures S1C and S1D). As
important controls, CM obtained from freshly isolated human
CRC cells, established CRC cell lines (HCT116 and HT29), or
fibroblasts were not able to significantly enrich the CSC popu-
lation in CRC cells (data not shown). Taken together, these
data suggest that EC-derived soluble factor(s) can promote
the CSC phenotype of CRC cells in a paracrine manner.
We next sought to understand whether ECs promote the
colorectal CSC phenotype either by converting a subset of
CRC cells into CSCs or by expanding the CSC population. We
sorted xhCRC cells by the Aldefluor assay and treated Alde-
fluor-high, -middle, and -low fractions with LPEC CM in parallel;
the Aldefluor assay was repeated and sphere forming assay
was performed to determine which ALDH population could be
enriched for CSCs by EC CM. Interestingly, we found that the
CSC population enrichment only occurred in the Aldefluor-
middle population, but not in Aldefluor-high (presumably
CSCs) or -low populations (presumably terminally differentiated
cells) (Figure 1G). Similar results were obtained using another
colorectal CSC marker, CD133, as the readout (Figure 1H).
These data suggest that the EC CM-mediated promotion of
the CSC phenotype is primarily achieved in nonstem CRC cells
that retain cellular plasticity. We also assessed levels of intestinal
differentiationmarker expression using quantitative reverse tran-
scription polymerase chain reaction (q-RT-PCR) and found that
LPEC CM treatment significantly reduced the expression of
Keratin 20 (KRT20) by 8-fold in hCRC cells (Figure S1E). In addi-
tion, we tested the expression levels of additional differentiation
markers, ANPEP and PRSS7, and found that their expression
levels, although easily detectable by qRT-PCR in cells treated
with control CM, were not detectable in the LPEC CM treated
group. These findings indicate that LPECCMpromotes the colo-
rectal CSC phenotype by inducing dedifferentiation in a subset
of nonstem CRC cells.d the CD133-positive xhCRC cell population was determined.
d the xhCRC sphere-forming assay was performed.
conditioned medium (CM), and the Aldefluor-positive cell population was
itionedmedium (CM), and the CD133-positive cell population was determined.
ells treated with LPEC CM.
low cell populations (upper panel). The Aldefluor-high, -middle, and -low cell
epeated (middle panel) and sphere forming assay was performed (lower panel)
er panel). The CD133-high, -middle, and -low fractions were treated with LPEC
nel) and sphere forming assay was performed (lower panel) to determine which
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Figure 2. Endothelial Cells Promote the CSC Phenotype of CRC Cells In Vivo
(A) In vivo tumorigenicity assay with limited dilution using HT29 cells pretreated with control CM or LPEC CM.
(legend continued on next page)
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Tumorigenicity and Metastasis of CRC Cells In Vivo
A critical experiment for determining the CSC phenotype is the
in vivo tumorigenicity assay by serial dilution (Clarke et al.,
2006). Therefore, we sought to validate our in vitro findings by
using an in vivo model. To this end, CRC cells pretreated with
either EC CM or control CM were serially diluted and injected
subcutaneously into mice, and tumorigenicity was determined.
LPEC CM-pretreated HT29 cells led to earlier tumor formation,
as well as greater tumor incidence and growth, compared with
control (HT29 CM pretreated) cells (Figure 2A). Similar results
were obtained when we compared the effect of RF24 CM on
HCT116 tumorigenicity (data not shown). We further extended
our study using serial passaging of cells in xenograft experi-
ments with freshly isolated xenografted hCRC (xhCRC) cells,
combined with limited dilution, and found that xhCRC cells pre-
treated with LPEC CM demonstrated significantly increased
tumorigenicity compared with those pretreated with control
medium, in both primary and secondary xenografts (Figure 2B).
We also investigated the effect of EC CM on the metastatic
potential of CRC cells. First we employed a tail vein injection
experiment, and found that, compared to control (HCT116 CM
treated) cells, RF24 CM-treated HCT116 CRC cells formed
significantly more metastases (Figures S2A and S2B). We then
used a splenic injection model to induce liver metastasis, the
most common site of CRC metastasis. Compared with xhCRC
cells treated with control medium, xhCRC cells treated with
LPEC CM demonstrated an increased incidence of liver metas-
tasis (nine of ten in the LPEC CM pretreatment group, compared
with three of ten in the control group; p < 0.05) (Figure 2C) and
a significantly increased tumor burden, as demonstrated by an
increase in luciferase activity (Figure 2D) and a 57% increase in
liver weight (photographs in Figure 2C) (Figure S2C; p < 0.05).
Collectively, these data demonstrated that EC-derived soluble
factor(s) promote the metastatic potential of CRC cells injected
in the spleen.CD133-Positive CRC Cells Are Located Adjacent to ECs
in Human Surgical Specimens
Having established that ECs secrete soluble factors to enrich
CRC cells with CSC phenotype, we sought to determine whether
CRC cells that express the CSCmarker CD133 are located in the
perivascular regions in human CRC surgical specimens. Immu-
nofluorescent staining for CD133 and CD31 (endothelial cell
marker) was carried out in primary colon cancer specimens
and chemotherapy-naive human CRC liver metastases. CD133
staining identified CRC cells that were located in proximity to
CD31-positive ECs (Figure 2E). Further staining confirmed that
these CD133-positive cells were not pericytes or stroma cells
because CD133 staining did not costain with desmin (a pericyte
marker) (Figure S2D), nor did they costain with smooth muscle
actin (a marker of stroma and pericytes), CD3 (a marker of(B) In vivo tumorigenicity assaywith limited dilution combinedwith serial transplant
(C and D) Hepatic metastatic incidence and burden of xhCRC cells pretreated wit
(E) Representative immunofluorescent staining of CD133 andCD31 in human prim
panel). The highlighted regions in the upper panels are enlarged in the lower pan
See also Figure S2.
CT cells and lymphocytes), CD68 (a marker of monocytes and
macrophages), or myeloperoxidase (a marker of myeloid cells)
(Figures S2E–S2H). In addition, we costained with antibodies
to CD133 and EPCAM (an epithelial marker) and demonstrated
colocalization of these markers (Figure S2I). Cumulatively, these
immune-staining data show that, in clinical specimens, the
CD133-positive cells are epithelial but not stromal in origin.
These data showed that colorectal CSCs are located adjacent
to tumor vasculature, and this is consistent with our preclinical
data that ECs can mediate the colorectal CSC phenotype.
Endothelial Cell-Conditioned Medium Promotes
Chemoresistance of CRC Cells
Preclinical studies suggest that CSCs possess intrinsic proper-
ties that mediate their resistance to chemotherapy (Al-Hajj,
2007; Dallas et al., 2009; Wicha et al., 2006). We therefore
hypothesized that CRC cells pretreated with EC CM would
exhibit resistance to chemotherapeutic agents. To test this
hypothesis, HCT116 CRC cells were exposed to oxaliplatin
(2 mM) or 5-fluorouracil (5-FU, 2 mg/ml) in RF24 CM or control
medium for 96 hr; chemosensitivity was determined by MTT
assay. Compared with cells that were pretreated with control
medium, HCT116 cultured in RF24 CM demonstrated a signifi-
cantly higher survival rate after oxaliplatin or 5-FU treatment
(3 fold) (Figure 3A). Similarly, LPEC CM treatment for 72 hr
led to chemoresistance of xhCRC cells (Figure 3C). To further
validate the chemoprotective effect of EC CM on tumor cells,
chemotherapy-induced apoptosis in HCT116 cells was as-
sessed after the cells were treated with chemotherapy while
cultured in EC CM or control HCT116 CM for 48 hr. Annexin V
staining demonstrated a significant decrease of apoptotic
events in the HCT116 cells treated with oxaliplatin or 5-FU while
cultured in LPEC CM (28% to 6%with oxaliplatin treatment, and
43% to 15%with 5-FU treatment, respectively; data not shown).
Western blot analysis showed lower levels of cleaved poly ADP-
ribose polymerase (PARP) and cleaved Caspase 3 in HCT116
cells treated with oxaliplatin or 5-FU while cultured in RF24 CM
compared to control CM (Figure 3B). Similar results were
observed in xhCRC treated with 5-FU while cultured in LPEC
CM (Figure 3D).
Endothelial Cell-Conditioned Medium Activates the
Notch Pathway in CRC Cells In Vitro
To understand the underlying mechanism by which EC CM
promotes the CSC phenotype of CRC cells, we sought to
examine the activation of canonical CSC pathways such as
Notch (Katoh and Katoh, 2007), Wnt/beta-catenin (Vermeulen
et al., 2010), and Sonic hedgehog (Saif and Chu, 2010) in CRC
cells treated with EC CM. To this end, we infected HT29 cells
with a lentivirus containing a Hes-1 promoter-driven reporter
(Jarriault et al., 1995), TCF reporter, or a Gli reporter (Limgala
et al., 2009), and treated the cells with LPEC CM or controlation using freshly isolated xhCRCcells pretreatedwith control CMor LPECCM.
h control CM or LPEC CM in a splenic injection model (*p < 0.05, mean ± SEM).
ary CRC surgical specimens (left panel), and humanCRC livermetastases (right
els.
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Figure 3. Endothelial Cell-Conditioned Medium Promotes Chemoresistance of Colorectal Cancer Cells
(A) HCT116 cells treated with oxaliplatin or 5-FU in control CM or RF24 CM (MTT assay).
(B) Western blot analysis of the expression of proapoptotic markers in HCT116 cells treated with oxaliplatin or 5-FU in control CM or RF24 CM.
(C) xhCRC cells treated with oxaliplatin or 5-FU in control CM or LPEC CM (MTT assay).
(D) Western blot analysis of the expression of proapoptotic markers in xhCRC cells treated with 5-FU in control CM or LPEC CM.
*p < 0.05, mean ± SEM.
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the Hes-1 reporter but not the Gli or TCF reporter (Figure 4A).
Using the identical luciferase reporter assays, we also observed
increased Hes-1 promoter activity in xhCRC cells treated with
LPEC CM (Figure 4B) and HCT116 cells treated with RF24 CM
(Figure S3A). In addition, we found that following EC CM treat-
ment, protein levels of Notch intracellular domain (NICD) and
Hes-1 in CRC cells were significantly increased (Figures 4C,
S3B, and S3C). These data suggest that EC CM activates Notch
signaling in CRC cells.
To determine whether Notch activation is indeed responsible
for the promotion of the colorectal CSC phenotype by EC CM,
gamma secretase inhibitor X (GSI), which inhibits the liberation
of NICD, was added to RF24 CM during treatment of the CRC
cells. GSI treatment blocked EC CM-induced Notch signaling
activation and CSC enrichment, as demonstrated by the sup-
pression of both NICD upregulation and Aldefluor-positive cell
population increase (Figures S3D and S3E).
CRC Cells Adjacent to ECs in Human Specimens
Demonstrate Activation of Notch Signaling
Having established that ECs secrete soluble factors to activate
Notch signaling, we sought to determine whether CRC cells
located in perivascular regions in human tumor samples dis-
played Notch activation. Immunofluorescent staining for NICD176 Cancer Cell 23, 171–185, February 11, 2013 ª2013 Elsevier Inc.and CD31 was carried out in human CRC surgical specimens.
We found that tumor cells expressing NICD were predominantly
located in the perivascular region (Figure 4D). These NICD-posi-
tive cells are not pericytes because NICD staining does not
overlap with desmin staining (Figure S3F). Furthermore, coim-
munofluorescent staining of CD133 and NICD highlighted the
colocalization of CD133-positive and NICD-positive CRC cells
in the perivascular niches (Figure 4E).
ECs Secrete a Soluble Form of Jagged-1 to Promote the
CSC Phenotype in CRC Cells
Because the Notch signaling pathway in CRC cells was acti-
vated by soluble factors in EC CM, we sought to identify the
molecules that activate Notch signaling. Although Notch activa-
tion is thought to occur exclusively via a juxtacrine mechanism,
some studies reported the presence of soluble Notch ligands
with variable effects on Notch signaling (Hukriede and Fleming,
1997; Nickoloff et al., 2002; Sun and Artavanis-Tsakonas,
1997). In contrast to the classic view of Notch activation, our
studies suggested the presence of a soluble Notch ligand that
was an activator of Notch signaling. Therefore, we examined
the presence of the known Notch-1 ligands DLL4 and Jagged-
1 in EC CM using western blot analysis. Our results showed
that DLL4 was not differentially secreted by CRC cells and
ECs, but a significantly greater amount of Jagged-1 was
Figure 4. Endothelial Cells Activate Notch Signaling in Neighboring Colorectal Cancer Cells
(A) Promoter activity of Hes-1, Gli, and TCF in HT29 cells after treatment with control CM or LPEC CM.
(B) Hes-1 promoter activity in freshly isolated xhCRC cells treated with control CM or LPEC CM (*p < 0.05, mean ± SEM).
(C) NICD and Hes-1 expression in freshly isolated hCRC cells treated with control CM or LPEC CM.
(D) Representative immunofluorescent staining for NICD and CD31 in human primary CRCs (left panel) and CRC liver metastases (right panel). The highlighted
regions in the upper panels are enlarged in the lower panels.
(E) Representative immunofluorescent staining of NICD and CD133 in primary CRCs (left panel) and CRC liver metastases (right panel).
See also Figure S3.
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compared to that in HT29 and HCT116 CM (Figures 5A and
S4A). Because Notch-activating Jagged-1 is usually membrane
bound, we sought to determine whether the Jagged-1 in EC
CM was associated with microvesicles. Even after depletion of
microvesicles, Jagged-1 could still be detected in the RF24
CM supernatant (Figure S4B), suggesting that the Jagged-1
found in EC CM is not anchored on microvesicles.
To determine whether this soluble form of Jagged-1 is respon-
sible for the EC-mediated paracrine or angiocrine activation of
Notch signaling in neighboring cancer cells, we first used smallCinterfering RNA (siRNA) to knock down Jagged-1 expression
in LPEC cells and decrease secretion of soluble Jagged-1 in
LPEC CM (Figure 5B). CM collected from Jagged-1 siRNA- or
control (scrambled) siRNA-transfected LPECs were applied to
HT29 cells for 72 hr, and activation of Notch signaling pathway
and the CSC phenotypes were then assessed. Depletion of
Jagged-1 in LPEC CM by siRNA blocked the EC CM-mediated
activation of Notch signaling in HT29 cells, as demonstrated by
the decreased expression of NICD and Hes-1, compared with
that in controls (Figure 5C). Furthermore, depletion of Jagged-1
in LPEC CM also blocked its effect on promotion of the CSCancer Cell 23, 171–185, February 11, 2013 ª2013 Elsevier Inc. 177
Figure 5. Endothelial Cells Secrete a Soluble Form of Jagged-1 to Promote the CSC Phenotype in Colorectal Cancer Cells
(A) Western blot analysis of HT29 and LPEC cell lysates and conditioned medium utilizing antibodies to the N terminus and C terminus regions of Jagged-1
(JAG1). Western blotting for DLL4 was also performed.
(B) Detection of soluble Jagged-1 in the conditioned medium from HT29 cells and LPECs after siRNA-mediated Jagged-1 knockdown.
(C) NICD and Hes-1 expression in HT29 cells after treatment with control CM or LPEC CM with decreased Jagged-1 levels by siRNA knockdown.
(D) Sphere-forming assay of HT29 cells exposed to control CM or LPEC CM with decreased Jagged-1 levels by siRNA knockdown.
(E) Sphere-forming assay of freshly isolated xhCRC cells exposed to control CM or LPEC CM with decreased Jagged-1 levels by siRNA knockdown.
(F) Sphere-forming assay of freshly isolated xhCRC cells exposed to the LPEC CM that is Jagged-1 depleted by immunoprecipitation.
*p < 0.05, mean ± SEM. See also Figure S4.
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blockade of sphere-forming ability (Figures 5D and 5E). Similarly,
depletion of Jagged-1 in RF24 CM by siRNA (Figure S4C)
blocked the activation of Notch signaling (Figure S4D) and
blocked enrichment of the Aldefluor-positive cells and increase
of sphere-forming ability (Figures S4E and S4F).
We also used an immunoprecipitation-based approach to
deplete Jagged-1 in EC CM to determine whether Jagged-1
was responsible for promoting the CSC phenotype. Following
depletion of soluble Jagged-1 in EC CM by an antibody recog-
nizing the N terminus of Jagged-1 (Figure S4G), the EC CM178 Cancer Cell 23, 171–185, February 11, 2013 ª2013 Elsevier Inc.was no longer able to enrich for cells with sphere-forming capa-
bility in xhCRC cells and HCT116 cells (Figures 5F and S4H). In
a follow-up study, we added a Jagged-1 neutralizing antibody
directly to the LPEC CM, and it blocked the enrichment of the
sphere forming population in freshly isolated xhCRC cells (data
not shown).
We obtained additional confirmation that the soluble form of
Jagged-1 secreted by ECs is indeed the major factor that acti-
vates Notch signaling and promotes the CSC phenotype in
neighboring CRC cells. First, we fractionated LPEC CM using
size exclusion-fast protein liquid chromatography and
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a Hes-1 promoter driven luciferase reporter assay. As is shown
in Figure 6A, we identified a single bioactive peak covering the
fractions 32–34 that induced Notch signaling. Simultaneously,
we examined the presence of soluble Jagged-1 in the various
fractions by western blotting, and found that the soluble
Jagged-1 containing fractions corresponded directly to the
fractions (32–34) that activated the Hes-1 reporter (Figure 6A).
Second, we immunoprecipitated Jagged-1 from EC CM and
ran the IP sample in a polyacrylamide gel electrophoresis
(PAGE) gel. After staining with Coomassie blue, we observed
a single band representing Jagged-1 (data not shown). Next,
we ran both native and denatured LPEC CM protein samples
on a nondenaturing PAGE gel, and blotted for Jagged-1 by
western blotting. As shown in Figure S5A, the soluble form of
Jagged-1 secreted by ECs is not stably associated with other
proteins. These data indicate that the soluble form of Jagged-1
that we identified is the Notch activating molecule in EC CM.
The EC-Secreted Soluble Form of Jagged-1 Is
a C-Terminally Truncated Protein
In CRC and EC cell lysates, intact Jagged-1 could be detected
by both Jagged-1 N terminus-specific and C terminus-specific
antibodies. However, soluble Jagged-1 in EC CM could only
be detected by the N terminus-specific antibody (Figures 5A
and S4A). After deglycosylation, the molecular weight of
soluble Jagged-1 in CM was 15–20 kDa smaller than that of
full-length Jagged-1 (Figure S5B). These results suggest that
this soluble Jagged-1 is a C-terminally truncated form.
In order to gain insights into whether this C-terminally trun-
cated form of soluble Jagged-1 is relevant in human CRCs,
we stained human CRC specimens using an antibody against
either N-terminal or C-terminal Jagged-1; we simultaneously
stained tissue sections with an antibody against the endothelial
cell marker CD31. As shown in Figure S5C, staining with the
C-terminal Jagged-1 antibody, which only reacts with full-length
Jagged-1, largely overlaps with CD31 staining. In contrast, the
N-terminal Jagged-1 antibody, which recognizes both full-length
and soluble Jagged-1, not only costains CD31-positive ECs, but
also strongly stains areas that are adjacent to ECs. These data
support the existence of soluble Jagged-1 in human CRCs.
We then sought to determine the nature of the soluble
Jagged-1 protein enriched in the EC CM. First, we asked
whether soluble Jagged-1 was a product of alternative splicing.
We performed semiquantitative RT-PCR to detect Jagged-1
splicing variants in CRC cells and ECs and excluded this possi-
bility because these two types of cells expressed equal levels of
the alternatively spliced Jagged-1 mRNA (Figure S5D). We then
hypothesized that a posttranslational event leads to
the generation of this soluble Jagged-1. When we transfected
full-length Jagged-1 cDNA into LPEC cells, an increase of
soluble Jagged-1 secretion in its CM was observed (data not
shown). Compared with the CM of mock-transfected LPECs,
CM collected from LPECs with Jagged-1 overexpression could
further promote the CSC phenotype of HT29 cells, as demon-
strated by a further enrichment of the Aldefluor-positive cell
population (data not shown). We then treated LPECs and RF24
cells with a protease inhibitor cocktail and found that broad-
spectrum inhibition of protease activity resulted in reduction ofCthe soluble Jagged-1 generation (Figure S5E), suggesting that
EC-secreted soluble Jagged-1 is a product derived from
protease cleavage of full-length Jagged-1. Taken together,
these results suggest that ECs are capable of posttranslational
modifications that lead to the production of this soluble form of
Jagged-1.
Proteomic Analysis of Soluble Jagged-1
In order to further define the structure of the soluble Jagged-1
protein, we employed a mass spectrometry-based strategy.
Briefly, we isolated the Jagged-1 proteins from LPEC CM via
immunoprecipitation using anN-terminal antibodyand subjected
them to deglycosylation followed by proteolytic digestion. Mass
spectrometry identified multiple peptides consistent with the
Jagged-1 amino acid sequence (Figure 6B), confirming the iden-
tity of soluble Jagged-1 protein in the EC CM. In addition, we
identified a peptide ‘‘KRDGNSSLIAAVAE’’ bearing only one
Lys-N site, indicating that the possible C terminus of soluble
Jagged-1 was at amino acid E1054. The identical proposed
C-terminal peptide was also found in protein samples isolated
by immunoprecipitation of N-terminal Jagged-1 from CM of
a second endothelial cell line, RF24, indicating that this EC-
secreted soluble form of Jagged-1 might be truncated at amino
acid 1054 (Figure 6B).
ADAM17 Cleaves Jagged-1 on ECs to Produce the
Soluble Form Jagged-1
A recent study reported that the protease ADAM17 could
mediate Jagged-1 shedding (Parr-Sturgess et al., 2010); how-
ever, the investigators did not describe the specific cleavage
site or the function of this cleaved product. Interestingly, by
analyzing the protein sequences flanking E1054 of Jagged-1
(Figure 6B), we found that VAEV is a plausible recognition
motif for the protease ADAM17, which may cleave the protein
between E1054 and V1055 (Caescu et al., 2009). Therefore, we
hypothesized that ADAM17 is the protease that cleaves
Jagged-1 in ECs to generate the soluble form of the protein.
To test our hypothesis, we first synthesized a peptide con-
sisting of aa 1047–1061 (SLIAAVAEVRVQRRP) of Jagged-1
and subjected it to ADAM17 cleavage followed by mass
spectrometry analysis. After ADAM17 cleavage, a 906.56 Da
peptide was identified and determined to be VRVQRRP (Fig-
ure 6C, middle panel); this cleavage was inhibited by TAPI-2,
an inhibitor of ADAM17 (Figure 6C, right panel). These data
confirm that ADAM17 specifically cleaves Jagged-1 between
residues E1054 and V1055.
We next cotransfected full-length human Jagged-1 and
ADAM17 expression plasmids into a mouse fibroblast cell line,
L cells. As shown in Figure S6A, we found that the soluble form
of Jagged-1 was enriched in the conditioned medium (here we
used two different antibodies that recognize the N terminus of
Jagged-1, to rule out any possibility of a none-specific signal
with the use of a single antibody); this conditionedmedium could
promote the CSC phenotype of freshly isolated hCRC cells,
as documented by CD133 FACS analysis (Figure S6B) and
sphere-forming ability (Figure S6C). These data confirm that
ADAM17 could cleave full-length Jagged-1, leading to extracel-
lular release of the soluble form of Jagged-1, which is sufficient
to promote the colorectal CSC phenotype.ancer Cell 23, 171–185, February 11, 2013 ª2013 Elsevier Inc. 179
Figure 6. Proteomics Analysis Demonstrate that the EC-Secreted Soluble Form of Jagged-1 Is C-terminally Truncated by ADAM17
(A) Concentrated LPEC CM was fractionated by FPLC gel filtration. The fractions were applied to xhCRC cells containing the Hes-1 promoter-luciferase
construct, and Hes-1 promoter activity was assessed (upper panel). Western blot detection of soluble Jagged-1 in combined adjacent fractions is shown in the
lower panel.
(B) Jagged-1 from LPEC CMwas immunoprecipitated using an N-terminal antibody and subjected to deglycosylation followed by digestion. Mass spectrometric
analysis of Jagged-1 proteins was performed with multiple peptides identified to be consistent with the N-terminal region of Jagged-1 with a C terminus at amino
acid E1054.
(legend continued on next page)
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Figure 7. Inhibition of ADAM17 in Endothe-
lial Cells Blocks the Conditioned Medium
Promotion of the CSC Phenotype in Human
CRC Cells
(A) Western blot detection of ADAM17 in the cell
lysate of LPECs treated with control or ADAM17
siRNA (left panel). The soluble form of Jagged-1 in
the CM from the cells shown in the left panel, are
shown in the right panel.
(B) Secretion of the soluble form of Jagged-1 into
the CM of HT29 cells and LPECs treated with the
ADAM17 inhibitor TAPI-2.
(C and D) Sphere-forming assays on HT29 cells (C)
and freshly isolated xhCRC cells (D) after treat-
ment with CM from LPECs, with or without the
ADAM17 inhibitor TAPI-2 (*p < 0.05, mean ± SEM).
(E) In vivo tumorigenicity assay (day 10) using
freshly isolated xhCRC cells coinjected with
LPECs with/without daily TAPI-2 treatment (*p <
0.05, LPEC/no TAPI-2 versus all other groups).
See also Figure S6.
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ECs that Promotes the Colorectal CSC Phenotype by
Blocking Soluble Jagged-1 Production
We sought to investigate whether inhibition of ADAM17 could
suppress the EC-mediated promotion of colorectal CSC pheno-
type by blocking Jagged-1 production. We knocked down
ADAM17 expression in LPECs by siRNA and found that this
resulted in a significant decrease in the production of soluble
Jagged-1 in LPEC CM (Figure 7A). We then used the ADAM17
inhibitor TAPI-2 to determine whether inhibition of ADAM17
activity would block production of soluble Jagged-1. Treatment
of LPECs with TAPI-2 significantly reduced soluble Jagged-1
production in its CM (Figure 7B). Importantly, TAPI-2 also in-
hibited the angiocrine effect of LPECs that promotes the
CSC phenotype of CRC cells, as demonstrated by decreased
enrichment of sphere-forming populations in HT29 cells and
freshly isolated xhCRC cells (Figures 7C and 7D). These studies(C) Mass spectrometric analysis of the ADAM17 cleavage site of Jagged-1. A synthetic peptide correspondin
buffer only (left panel), ADAM17 (middle panel), or ADAM17with its inhibitor TAPI-2 (right panel), and the reacti
Peak 1 represents the intact substrate SLIAAVAEVRVQRRP, and Peak 2 represents the ADAM17 cleavage pr
be VRVQRRP.
See also Figure S5.
Cancer Cell 23, 171–185,confirm that ADAM17 is essential for
soluble Jagged-1 production by ECs.
Finally, we performed an in vivo study
using xenograft models to determine
whether inhibition of ADAM17 can block
the angiocrine promotion of tumorige-
nicity. We coinjected freshly isolated
xhCRC cells with LPECs subcutaneously
into mice and treated the animals with
daily TAPI-2 by intraperitoneal (IP) injec-
tion. We found that TAPI-2 treatment
significantly suppressed tumor initiation
(Figure 7E). These data suggest that
ADAM17mediated shedding of Jagged-1from ECs is an important mechanism that mediates the angio-
crine effect on tumor initiation.
Taken together, our data suggest that ADAM17 is the pro-
tease that cleaves Jagged-1 in ECs, and the resultant soluble
Jagged-1 functions in a paracrine manner to activate Notch
signaling and promote the CSC phenotype of nearby CRC cells.
DISCUSSION
The concept of targeting the tumor vasculature as an antineo-
plastic strategy was developed 40 years ago by Folkman
(Folkman, 1971). However, therapeutic agents targeting classic
angiogenic mediators, such as vascular endothelial growth fac-
tor, have only minimally improved progression-free and overall
survival when added to chemotherapy regimens for patients
with metastatic CRC (Saltz et al., 2008). Although tumor vascu-
larity correlates with the aggressiveness of CRC, this does notg to aa 1047–1061 of Jagged-1 was incubated with
on products were subjected tomass spectrometry.
oduct, a 906.56 Da peptide that was determined to
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shi et al., 1995; Weidner et al., 1991). It is possible that ECs play
a more active role in mediating tumor growth and metastasis
than simply providing the physical structure that forms conduits
for blood flow. The development of more effective agents target-
ing the vasculature may require approaches that go beyond tar-
geting the classic angiogenic pathways by current means.
Here, we provide several lines of evidence demonstrating that
ECs secrete soluble factors that promote the colorectal CSC
phenotype via a paracrine effect: CM derived from ECs can (1)
enrich the Aldefluor-positive CRC cell population, (2) enrich
CRC cells expressing putative colorectal CSC surface marker
CD133, (3) increase CRC cell sphere-forming capability, (4)
enhance tumorigenicity, and (5) confer chemoresistance to
CRCcells.We also determined that themajor EC-secreted factor
that promotesCSCphenotype is anunreported formof Jagged-1
that activates Notch signaling in neighboring CRC cells.
The identification (or existence) of CSCs remains a point of
controversy. Numerous markers have been used to identify
CSCs from CRC specimens, including the cell surface marker
CD133, functional studies such as the Aldefluor assay and
sphere-forming ability, and in vivo studies such as the serial dilu-
tion-based tumorigenicity assay. In our studies, we assessed all
of these markers, and all confirmed that ECs secrete a factor(s)
that increase the percentage of CRCs with CSC properties. We
believe the tumorigenicity and chemoresistance assays are the
most important studies that potentially have clinical implications.
Many studies suggest that CSCs originate from mutations in
stem cells that cause malignant transformation (Barker et al.,
2009; Dick, 2008; Korkaya and Wicha, 2010; Passegue´ et al.,
2003). However, other investigators have noted that CSCs exist
in a state of flux and that the CSC population can be enriched by
microenvironmental influences (Chaffer et al., 2011; Rosen and
Jordan, 2009; Vermeulen et al., 2010). In our studies, EC CM
increased the percentage of cells with CSC characteristics,
further supporting the idea that the microenvironment can regu-
late the CSC phenotype. Our findings that EC CM can convert
a non-CSC to a cell with CSC properties are in line with recent
studies showing that CSCs and non-CSCs do not exist in fixed
states (Chaffer et al., 2011; Gupta et al., 2011). More importantly,
we demonstrated that Notch signaling activation by a soluble
ligand is an important mechanism through which the CSC pop-
ulation is enriched in CRC by the microenvironment.
The observation that CSCs accumulate in perivascular regions
has been reported by several groups (Butler et al., 2010a; Cal-
abrese et al., 2007; Krishnamurthy et al., 2010). EC-secreted
factors have been shown to promote the self-renewal of CSCs
in squamous cell carcinomas, as demonstrated by upregulated
Bmi-1 expression and an increase in sphere formation in vitro
(Krishnamurthy et al., 2010). Others have shown that ECs could
promote glioblastoma stem-like cell expansion by secreting
factors that activate mTOR signaling (Galan-Moya et al., 2011).
These studies support the notion that tumor-associated ECs
play a direct role in maintaining a population of CSCs. We
demonstrated that ECs produce a truncated soluble form of
Jagged-1 that activates Notch signaling in CRC cells to promote
their CSC phenotype. We also showed that, in both primary and
metastatic human CRC specimens, NICD- and CD133-positive
cells are primarily located in perivascular areas. Our findings182 Cancer Cell 23, 171–185, February 11, 2013 ª2013 Elsevier Inc.suggest that ECs play an important role in establishing a peri-
vascular niche for colorectal CSCs through inducing Notch
signaling in tumor cells by releasing soluble Jagged-1 in a para-
crine manner.
Rafii and colleagues reported that EC expression of Jagged-1
and Jagged-2 could stimulate the expansion of Notch-depen-
dent hematopoietic stem cells (Butler et al., 2010b). Similarly,
Fan’s group reported that human brain microvascular ECs could
activate Notch signaling in adjacent glioblastoma cells in a juxta-
crine manner (Zhu et al., 2011). Taketo and colleagues also re-
ported that tumor-associated ECs express Jagged-1 and DLL4
that activate Notch signaling on CRC cells (Sonoshita et al.,
2011). In these studies, direct cell-cell contact (juxtacrine sig-
naling) was required for ECs to maintain hematopoietic/cancer
stem cell propagation (Butler et al., 2010b; Kobayashi et al.,
2010). In our studies, however, we defined a previously unrecog-
nized mechanism through which ECs activate Notch signaling to
promote CRC cell stemness—namely, production of a soluble
paracrine/angiocrine Notch ligand.
In this study, we were able to determine the identity of the
soluble form of Jagged-1 secreted by ECs, produced through
ADAM17 cleavage. In addition, we determined that this soluble
form of Jagged-1 activates Notch signaling and, in turn, medi-
ates the CSC phenotype of CRC cells. In the classic model of
Notch signaling (Figure 8A), Notch is activated by cell surface-
bound ligands, where cell-cell contact is required. We propose
an alternative Notch activation model, as shown in Figure 8B,
whereby the full-length Jagged-1 is cleaved by ADAM17, which
results in the production of a truncated soluble form of Jagged-1
that can activate Notch signaling in nearby cells. This manner
of Notch pathway activation does not require cell-cell contact,
and therefore, we refer it as paracrine/angiocrine activation of
Notch.
Several studies have reported contrasting biologic effects of
soluble Notch ligands. Two groups generated soluble mutants
of Drosophila Notch ligands Delta and/or Serrate and found
that these forms could function as antagonists of Notch signaling
(Hukriede and Fleming, 1997; Sun and Artavanis-Tsakonas,
1997). Similarly soluble forms of human Jagged-1 and DLL1
composed only of the extracellular domain were reported to
inhibit Notch signaling (Small et al., 2001; Trifonova et al.,
2004). An engineered soluble Notch ligand, DLL4-Fc, in which
the extracellular domain of DLL4 was fused to a human IgG1
Fc fragment, has been shown to inhibit Notch activation (Lobov
et al., 2007; Noguera-Troise et al., 2006). In contrast, several
groups have shown that soluble Jagged1-derived peptides are
able to activate Notch signaling in several cell types, leading to
keratinocyte differentiation (Nickoloff et al., 2002), maturation
of dendritic cells (Weijzen et al., 2002), apoptosis in B cell
leukemia cells (Kannan et al., 2011), and inhibited differentiation
of hematopoietic precursor cells (Li et al., 1998). Importantly,
a naturally occurring soluble form of Jagged1 was found in
human skin, inducing epithelial differentiation, a phenotype
consistent with Notch activation (Aho, 2004). We found a natu-
rally occurring soluble Jagged-1 that can activate Notch sig-
naling in CRC cells. The reasons for the apparent discrepancies
among different studies are not well understood. A major deter-
minant of whether a soluble ligand activates or inhibits Notch
signaling could be the specific structure of the ligand. Thus, we
Figure 8. Proposed Model for EC-Mediated
Paracrine Activation of Notch Signaling in
Colorectal Cancer Cells
(A) The conical model for Notch pathway activa-
tion, where membrane bound ligands such as
Jagged-1 activates Notch signaling in contacting
cells.
(B) Schematic summarizing our proposed model
for paracrine activation of the Notch pathway in
CRC cells. ADAM17 cleaves membrane bound
Jagged-1 on ECs, releasing an N-terminal soluble
fragment that binds, and activates, Notch on CRC
cells.
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from different species, cleavages, posttranslational modifica-
tions, and/or engineering strategies, may account for their dif-
ferent biologic behaviors.
Although Notch inhibitors are being studied in clinical trials,
toxicity has been noted, limiting clinical development. Our
discovery of truncated soluble form of Jagged-1 that activates
Notch signaling in CRC cells has potential clinical implications.
Neutralization of Notch activation triggered by soluble Jagged-1
may be amore specific and refined approach to sensitize tumors
to antineoplastic therapies.
Although we believe that soluble Jagged-1 is the major factor
that mediates the angiocrine effect that promotes the colorectal
CSC phenotype, we do not exclude the possibility that other
signaling events may also contribute to induction of the CSC
phenotype. Given the obvious complexity of tumor microenvi-
ronment, we believe that other important angiocrine factors
remain to be identified, and this will be important in the develop-
ment and refinement of new therapeutic approaches.
In summary, our study defines a mechanism for the angio-
crine function of ECs that leads to Notch activation that, in
turn, promotes the CSC phenotype. This study reports the
generation of an active, soluble form of Jagged-1 that is the
product of ADAM17 protease activity. Our findings, along with
other studies in the field of angiocrine signaling, suggest that
ECs are more than simply conduits for nutrient and oxygen
delivery—they also contribute soluble factors to promote the
CSC phenotype and chemoresistance. It is possible that target-
ing angiocrine signaling, including soluble Jagged-1 and/or
ADAM17, may improve the outcomes of therapy for patients
with metastatic CRC.
EXPERIMENTAL PROCEDURES
Isolation of Human CRC Cells and Liver Parenchyma ECs
Human CRC (hCRC) cells and LPECs were isolated from CRC and liver
parenchyma tissue from surgical specimens, respectively. Xenografted
human CRC (hxCRC) cells were isolated from mice after a direct inoculation
with freshly isolated human CRC cells derived from patients (see Supple-
mental Experimental Procedures). The M.D. Anderson Cancer CenterCancer Cell 23, 171–185,(MDACC) Institutional Review Board approved
human specimen procurement, and informed
consents were obtained.
Tumorigenicity Studies
All mice were housed in the MDACC animal
facility, and all experiments were performed inaccordance with guidelines approved by the MDACC Institutional Animal
Care & Use Committee. LPEC CM-pretreated xhCRC cells were injected
subcutaneously into nude mice. Primary xenografts were harvested and
treated with LPEC CM for 7 days before secondary xenograft passaging
(see Supplemental Experimental Procedures). Tumor growth was monitored
by a blinded investigator.
In Vivo Metastasis Studies
Luciferase-labeled CRC cells were pretreated with EC CM for 7 days and in-
jected intravenously (Saltz et al., 2008) via tail vein or via the spleen (liver
metastasis model). Luciferase activity was used to assess the relative tumor
burden (see Supplemental Experimental Procedures).
Statistical Analysis
For all in vitro and ex vivo experiments, statistical analyses were conducted
using Student’s t test (Microsoft Excel). For in vivo studies, statistical analyses
were performed using the Kaplan Meier test (Software R) (tumorigenicity), chi-
square test (Microsoft Excel) (tumor incidence), and Mann Whitney-U test
(number of metastatic sites and tumor burden). All statistical tests were two-
sided, and p values% 0.05 were considered to be significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and may be found with this article online at http://dx.doi.org/10.
1016/j.ccr.2012.12.021.
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